Publication date: Jan 17, 2025
The onset of the COVID-19 pandemic has had a detrimental impact on the healthcare system. Patients with kidney failure and related kidney disease are notably vulnerable to the COVID-19 pandemic. However, it remains unclear how mortality trends associated with kidney failure have evolved over the past three years. In this study, we investigated temporal trends in excess kidney failure-related mortality during the first three years of the pandemic in the United States. We aim to estimate time-varying excess kidney failure-related mortality, which is defined as the difference between observed mortality and expected mortality predicted by a Poisson log-linear regression model, in the United States (March 2020-March 2023). Our findings revealed two distinct peaks in excess kidney failure-related mortality during the first year (March 2020-February 2021) and the second year (February 2021-March 2022), whereas a notable decline in excess mortality was observed in the third year (March 2022-March 2023). Additionally, disparities in mortality were evident among various demographic groups, including age, sex, racial/ethnic subgroups, and geographic regions. Across all age subgroups, an increase in kidney failure-related mortalities was observed, with individuals aged 85 years and above experiencing the most substantial relative increase, reaching 9595. 8 per million persons (95% CI: 9438. 8, 9752. 9). Moreover, excess kidney failure-related mortalities were recorded at 510. 3 per million persons (95% CI: 502. 6, 517. 9) and 721. 8 per million persons (95% CI: 713. 4, 730. 1) for women and men, respectively. Notably, non-Hispanic Blacks exhibited the highest excess mortality within the racial/ethnic group, registering at 772. 6 per million persons (95% CI: 756. 3, 788. 9). Our study observed high levels of excess kidney failure-related mortality during the first two years of the pandemic, followed by a notable decline in the third year. This highlights the effectiveness of current policies and prevention measures implemented to mitigate the impact of the pandemic.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Kidney failure |
disease | MESH | COVID-19 pandemic |
disease | MESH | kidney disease |
pathway | REACTOME | Reproduction |
drug | DRUGBANK | (S)-Des-Me-Ampa |
drug | DRUGBANK | Tretamine |
disease | MESH | infection |
drug | DRUGBANK | Fenamole |
disease | MESH | complications |
disease | MESH | death |
disease | IDO | process |
disease | MESH | panic |
drug | DRUGBANK | Ethionamide |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Trestolone |
disease | MESH | emergency |
drug | DRUGBANK | Ritonavir |
disease | IDO | immune response |
disease | MESH | uncertainty |
drug | DRUGBANK | Etoperidone |
disease | MESH | acute kidney injury |
disease | IDO | cell |
disease | MESH | thrombosis |
drug | DRUGBANK | Ranitidine |
disease | MESH | Chronic kidney disease |
disease | MESH | muscle atrophy |
drug | DRUGBANK | Silver |
drug | DRUGBANK | Kale |